Jean-Louis Anspach has been named president, Eurand Pharmaceuticals, Inc. Mr. Anspach is a 25-year veteran of the specialty pharmaceutical and chemical industries and was most recently executive vice president, Marketing at Solvay Pharmaceuticals, which was acquired by Abbott Laboratories in February 2010. He will be based at EPI’s commercial headquarters in Yardley, PA.

“We are delighted to welcome Jean-Louis to the Eurand team,” said Gearóid Faherty, Eurand’s chairman and chief executive officer. “He combines strong managerial and leadership skills with a broad background in the specialty pharmaceutical sector that includes several successful product launches. We believe his expertise and experience in developing and executing effective, impactful business plans and marketing strategies will serve Eurand well both for the ongoing launch of ZENPEP and for the future of our U.S. commercial operations.”

At Solvay, Mr. Anspach successfully led the development and execution of business plans for the cardio-metabolic, neuroscience, gastroenterology, women’s health and specialized markets franchises. His 25-year career at Solvay included positions of increasing scope and responsibility in general management, marketing, sales, business development, investor relations and corporate finance.

Michael Walters, executive vice president, Sales and Marketing, has resigned from the company to pursue other opportunities. Mr. Walters joined Eurand in December 2007 as part of the acquisition of Source CF, a specialized pharmaceutical company focused on the needs of cystic fibrosis patients, physicians and caregivers.

“We are grateful for Mike’s many contributions to Eurand, most notably his leadership role in the establishment of our commercial operations in the U.S.,” said Faherty. “We wish him all the best in his future endeavors.”